24.46

0.82% 0.20

Pre-market: 24.47 0.010 +0.04%

Spyre Therapeutics Inc (SYRE)

Overview News Price History Financials Discussions Forecast

Spyre Therapeutics Inc stock is traded at $24.46, with a volume of 683.32K. It is up +0.82% in the last 24 hours and up +45.94% over the past month. Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Previous Close:

$24.26

Open:

$24.1

24h Volume:

683.32K

Relative Volume:

0.85

Market Cap:

$1.48B

Revenue:

$688.00K

Net Income/Loss:

$-170.19M

P/E Ratio:

-8.021

EPS:

-3.0495

Net Cash Flow:

$-154.68M

1W Performance:

+4.66%

1M Performance:

+45.94%

6M Performance:

+60.60%

1Y Performance:

-24.81%

1-Day Range:

$23.65

$24.59

1-Week Range:

$23.52

$25.05

52-Week Range:

$10.91

$40.26

Spyre Therapeutics Inc Stock (SYRE) Company Profile

Name

Spyre Therapeutics Inc

Sector

Healthcare (1135)

Industry

Biotechnology (635)

Phone

(617) 651-5940

Address

221 CRESCENT STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

SYRE's Discussions on Twitter

Compare SYRE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SYRE Spyre Therapeutics Inc	24.46	1.88B	688.00K	-170.19M	-154.68M	-3.0495
VRTX Vertex Pharmaceuticals Inc	425.57	107.66B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	651.80	68.74B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	456.04	58.93B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	818.50	50.51B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	189.60	41.29B	447.02M	-1.18B	-868.57M	-6.1812

Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-26-25	Initiated	Deutsche Bank	Buy
Apr-08-25	Initiated	Leerink Partners	Outperform
Mar-18-25	Initiated	Wolfe Research	Outperform
Sep-04-24	Initiated	Wedbush	Outperform
Jul-16-24	Initiated	Evercore ISI	Outperform
May-02-24	Initiated	Robert W. Baird	Outperform
Mar-01-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-20-23	Initiated	BTIG Research	Buy
Dec-11-23	Initiated	Guggenheim	Buy
Dec-11-23	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
Mar-21-19	Initiated	JP Morgan	Overweight
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform
Mar-14-18	Reiterated	Needham	Buy

View All

Spyre Therapeutics Inc Stock (SYRE) Latest News

03:43 AM

Why retail investors favor Spyre Therapeutics Inc. stock2025 Valuation Update & Fast Moving Stock Trade Plans - newser.com

03:43 AM

Nov 02, 2025

Will Spyre Therapeutics Inc. (3920) stock sustain uptrend momentumWeekly Profit Analysis & AI Forecasted Stock Moves - newser.com

Nov 02, 2025

Is Spyre Therapeutics Inc. stock a buy for dividend growthJuly 2025 Setups & Weekly Breakout Stock Alerts - newser.com

Nov 02, 2025

Why Spyre Therapeutics Inc. stock remains on watchlistsPortfolio Risk Report & Real-Time Market Trend Scan - newser.com

Nov 02, 2025

Using Ichimoku Cloud for Spyre Therapeutics Inc. technicalsMarket Rally & Free Risk Controlled Daily Trade Plans - newser.com

Nov 02, 2025

How to escape a deep drawdown in Spyre Therapeutics Inc.July 2025 Weekly Recap & Technical Analysis for Trade Confirmation - newser.com

Nov 02, 2025

Is a relief rally coming for Spyre Therapeutics Inc. holdersWeekly Trade Report & Low Risk Investment Opportunities - newser.com

Nov 02, 2025

Can Spyre Therapeutics Inc. stock sustain free cash flow growth2025 Momentum Check & Safe Capital Preservation Plans - newser.com

Nov 02, 2025

Will Spyre Therapeutics Inc. stock recover faster than peers2025 EndofYear Setup & Growth Focused Stock Reports - newser.com

Nov 02, 2025

What insider purchases suggest about Spyre Therapeutics Inc. (3920) stockMarket Trend Report & Fast Momentum Stock Entry Tips - newser.com

Nov 02, 2025

Published on: 2025-11-02 03:35:20 - newser.com

Nov 02, 2025

What dividend safety score for Spyre Therapeutics Inc. stock2025 Trading Volume Trends & Long-Term Growth Stock Strategies - newser.com

Nov 02, 2025

Nov 01, 2025

Is Spyre Therapeutics Inc. (3920) stock inflation resilient2025 Analyst Calls & Risk Managed Investment Signals - newser.com

Nov 01, 2025

Why Spyre Therapeutics Inc. stock remains undervalued2025 AllTime Highs & Smart Allocation Stock Tips - newser.com

Nov 01, 2025

Will Spyre Therapeutics Inc. stock deliver strong dividend growth2025 Geopolitical Influence & Daily Stock Trend Watchlist - newser.com

Nov 01, 2025

Earnings visualization tools for Spyre Therapeutics Inc.July 2025 Patterns & Community Consensus Trade Alerts - newser.com

Nov 01, 2025

What sentiment indicators say about Spyre Therapeutics Inc. stock2025 Price Momentum & Long-Term Safe Return Strategies - newser.com

Nov 01, 2025

Published on: 2025-11-01 04:11:34 - newser.com

Nov 01, 2025

Oct 31, 2025

Spyre Therapeutics (SYRE) to Release Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2025

Will Spyre Therapeutics Inc. stock maintain dividend yieldWeekly Trend Summary & Community Consensus Stock Picks - newser.com

Oct 31, 2025

What drives Spyre Therapeutics Inc 3920 stock priceInsider Buying Signals & Free Professional Investment Consultations - earlytimes.in

Oct 31, 2025

Will Spyre Therapeutics Inc. stock sustain high P E ratiosJuly 2025 Decliners & Expert Verified Stock Movement Alerts - newser.com

Oct 31, 2025